Document Detail


Bopindolol in the treatment of moderate hypertension: a dose-response study.
MedLine Citation:
PMID:  2906897     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine the optimal antihypertensive dose of bopindolol, we performed a randomized double-blind study in parallel groups. After 15 days of placebo single-blind, 115 hypertensive patients received daily for 28 days one of 4 doses: 0 mg (placebo), 0.5 mg, 1.0 mg, 2.0 mg. The reduction of supine diastolic blood pressure (BP) did not exhibit the pattern of a dose-effect relationship. The effect of 0.5 mg belonged to the plateau of the dose-effect curve (P = 0.1, analysis of variance). The reduction of heart rate (HR) followed a typical dose-effect curve, with a plateau beginning with 1 mg (P = 0.02). A trend toward an increase in the incidence of side-effects with dosage was observed (P = 0.3). Thus, the optimal antihypertensive dose may be 0.5 mg or less. Previous studies not using parallel randomized groups suggested an antihypertensive dose ranging from 2 to 4 mg. This study confirms that the dose-effect curves of beta blockers on HR and BP are dissociated. The dose-effect curve of HR seems unsuitable for assessing the optimal antihypertensive dose of a beta blocker.
Authors:
P Moleur; J C Peyrieux; J Luciani; D David; J P Boissel
Related Documents :
153477 - Chronic hypertension induced by streptozotocin in rats.
2447437 - Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids...
2442557 - Lisinopril in elderly patients with hypertension.
18441457 - Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on...
2047707 - Role of hepatocellular regeneration in ccl4 autoprotection.
736037 - Cytosine arabinoside modulation of the mitotic index in treatment of adult acute leukemia.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  2     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  1988  
Date Detail:
Created Date:  1989-04-27     Completed Date:  1989-04-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  431-40     Citation Subset:  IM    
Affiliation:
Unité de Pharmacologie Clinique de l'Hôpital Neurologique et Cardiologique, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  adverse effects
Blood Pressure / drug effects
Clinical Trials as Topic
Dose-Response Relationship, Drug
Double-Blind Method
Drug Tolerance
Female
Heart Rate / drug effects
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Pindolol / administration & dosage,  adverse effects,  analogs & derivatives*
Random Allocation
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 13523-86-9/Pindolol; 69010-88-4/bopindolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of promethazine on ischemic and reperfusion arrhythmias in rat heart.
Next Document:  Evaluation of the natriuretic and beta-adrenoceptor-blocking effects of tienoxolol in normal volunte...